American Society of Addiction Medicine
American Society of Addiction Medicine
Lead Story: Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
Lead Story: Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
Lead Story: Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
Tuesday 13th December 2022
Buprenorphine vs methadone for opioid use disorder in pregnancy: Buprenorphine shows better outcomes. Plus, insights on cannabis use, heart failure, and more.
7 minutes
Informative
Educational
Thought-provoking
Raw
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
169 (View all)
Do you want to link to this podcast?
Get the buttons here!Buprenorphine vs Methadone: Key Findings for Opioid Use Disorder in Pregnancy
This study found that buprenorphine treatment for opioid use disorder during pregnancy was associated with more favorable neonatal outcomes when compared to methadone treatment.
Ever wondered which treatment is better for opioid use disorder during pregnancy? This episode of 'Addiction Medicine Unpacked' tackles that very question. Drawing from a comprehensive study published in The New England Journal of Medicine, the episode reveals that buprenorphine leads to more favorable neonatal outcomes compared to methadone. The study, spanning from 2000 to 2018, shows that 69% of infants exposed to methadone experienced neonatal abstinence syndrome, whereas only 52% of those exposed to buprenorphine did.
Additionally, buprenorphine was linked to lower rates of preterm births and better overall birth weights. But that's not all. This episode dives into other fascinating topics in addiction medicine. One segment explores how media attention on cannabis-based therapies can skew public perception, leading to an increased placebo effect. Another study discussed highlights a rise in prenatal cannabis use during the COVID-19 pandemic, particularly in areas close to cannabis retailers.
Listeners will also hear about the challenges faced by individuals with co-occurring substance use disorders, who are less likely to receive necessary medications for opioid use disorder. Methamphetamine-associated heart failure is another critical topic covered, with findings showing that cessation of methamphetamine use can lead to significant heart recovery. The genetic factors influencing cannabis use are also examined, revealing that cannabis use is moderately heritable and linked to specific genetic variants.
Lastly, the episode touches on the adverse effects of ayahuasca, noting that many users report at least one negative physical or mental health effect. Whether you're a healthcare professional, someone affected by addiction, or simply curious about the latest in addiction medicine, this episode offers a wealth of knowledge and insights. Tune in to gain a deeper understanding of these complex issues and stay informed about the latest developments in the field.